CR10600A - Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa - Google Patents
Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasaInfo
- Publication number
- CR10600A CR10600A CR10600A CR10600A CR10600A CR 10600 A CR10600 A CR 10600A CR 10600 A CR10600 A CR 10600A CR 10600 A CR10600 A CR 10600A CR 10600 A CR10600 A CR 10600A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibitors
- protein kinase
- metoxyled
- pyrimidins
- cyclopenta
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81871806P | 2006-07-06 | 2006-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10600A true CR10600A (es) | 2009-02-20 |
Family
ID=38686743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10600A CR10600A (es) | 2006-07-06 | 2009-02-05 | Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa |
Country Status (34)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| SI2054418T1 (sl) | 2006-07-06 | 2012-02-29 | Array Biopharma Inc | Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji |
| JP5231410B2 (ja) * | 2006-07-06 | 2013-07-10 | アレイ バイオファーマ、インコーポレイテッド | Ａｋｔプロテインキナーゼ阻害剤としてのジヒドロフロピリミジン |
| AU2007269052B2 (en) | 2006-07-06 | 2014-10-23 | Array Biopharma Inc. | Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| WO2008115511A1 (en) | 2007-03-20 | 2008-09-25 | Peak Biosciences, Inc. | Method for therapeutic administration of radionucleosides |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| NZ582692A (en) | 2007-07-05 | 2012-05-25 | Array Biopharma Inc | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| WO2009006569A1 (en) | 2007-07-05 | 2009-01-08 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| CN104876921A (zh) * | 2008-01-09 | 2015-09-02 | 阵列生物制药公司 | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 |
| WO2009089454A1 (en) | 2008-01-09 | 2009-07-16 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| AU2009204025B2 (en) | 2008-01-09 | 2014-02-20 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| CN101932565B (zh) | 2008-01-09 | 2013-06-12 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的羟基化嘧啶基环戊烷 |
| CA2821378A1 (en) * | 2010-12-23 | 2012-06-28 | Genentech, Inc. | Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms |
| BR112013025397A2 (pt) * | 2011-04-01 | 2019-09-24 | Deepak Sampath | combinação de um composto, composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, uso, kit, produto, método para tratamento de um distúrbio hiperproliferativo e método para tratamento de uma doença ou afecção modulada por quinase akt em um mamífero |
| BR112013025386B1 (pt) * | 2011-04-01 | 2023-03-07 | Genentech, Inc | Uso de um composto, combinação, medicamento, produto e sistema |
| KR102165122B1 (ko) * | 2011-04-01 | 2020-10-13 | 제넨테크, 인크. | 암 치료에 대한 감수성을 예측하기 위한 바이오마커 |
| BR112014028570A2 (pt) | 2012-05-17 | 2018-04-24 | Array Biopharma Inc | processo para fabricação de compostos de ciclopentilpirimidina hidroxilada. |
| WO2013173784A1 (en) * | 2012-05-17 | 2013-11-21 | Genentech, Inc. | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof |
| WO2013173779A1 (en) * | 2012-05-17 | 2013-11-21 | Genentech, Inc. | Process for making amino acid compounds |
| RU2643811C2 (ru) | 2012-05-17 | 2018-02-06 | Аррэй Байофарма Инк. | Способ получения гидроксилированных циклопентилпиримидиновых соединений |
| US9290458B2 (en) * | 2012-05-17 | 2016-03-22 | Genentech, Inc. | Amorphous form of an AKT inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof |
| US20150258127A1 (en) | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| RU2015127037A (ru) * | 2012-12-07 | 2017-01-11 | Дзе Дженерал Хоспитал Корпорейшн | Комбинации ингибитора pi3k/akt с ингибитором her3/egfr и способы их применения |
| JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
| HRP20192340T1 (hr) | 2013-11-15 | 2020-04-03 | F. Hoffmann - La Roche Ag | Postupci za proizvodnju spojeva pirimidinilciklopentana |
| RU2712224C2 (ru) * | 2014-09-26 | 2020-01-27 | Ф. Хоффманн-Ля Рош Аг | Способы получения (циклопентил[d]пиримидин-4-ил)пиперазиновых соединений |
| CA3032233C (en) | 2016-08-10 | 2021-09-14 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions comprising akt protein kinase inhibitors |
| AU2017348322B8 (en) | 2016-10-28 | 2021-12-23 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating EZH2-mediated cancer |
| WO2019173516A1 (en) * | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| US12110295B2 (en) | 2018-06-21 | 2024-10-08 | Icahn School Of Medicine At Mount Sinai | WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use |
| US11701356B2 (en) | 2018-12-19 | 2023-07-18 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising an AKT inhibitor, a taxane, and a PD-L1 inhibitor |
| SG11202106635WA (en) | 2018-12-21 | 2021-07-29 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate and kinase inhibitor |
| AU2020214258B2 (en) | 2019-01-29 | 2025-08-28 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | AKT inhibitor |
| EP3946330A1 (en) | 2019-03-29 | 2022-02-09 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders |
| WO2020210337A1 (en) * | 2019-04-09 | 2020-10-15 | Dana-Farber Cancer Institute, Inc. | Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use |
| US12465648B2 (en) | 2019-05-06 | 2025-11-11 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as degraders of HPK1 |
| CA3167999A1 (en) * | 2020-03-17 | 2021-09-23 | Xin Li | Fused bicyclic derivative, preparation method therefor, and pharmaceutical use thereof |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| CN115916758A (zh) | 2020-06-16 | 2023-04-04 | 豪夫迈·罗氏有限公司 | 用于制备羟基化环戊基嘧啶化合物的方法 |
| EP4186902A4 (en) | 2020-07-22 | 2024-06-05 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE SALT, PREPARATION METHOD AND USE THEREOF |
| TWI750905B (zh) * | 2020-11-19 | 2021-12-21 | 財團法人國家衛生研究院 | 噻唑化合物作為蛋白質激酶抑制劑 |
| KR102689151B1 (ko) * | 2021-09-06 | 2024-07-29 | 연세대학교 산학협력단 | Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물 |
| WO2023043869A1 (en) * | 2021-09-15 | 2023-03-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of ipatasertib citrate |
| CN113788834B (zh) * | 2021-09-18 | 2022-11-29 | 河南奥思恩医药科技有限公司 | 2,4-二氯-6,7-二氢-5H-吡咯并[3,4-d]嘧啶盐酸盐的制备方法 |
| CN117677614A (zh) * | 2021-12-17 | 2024-03-08 | 中国医药研究开发中心有限公司 | 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途 |
| AU2023246862A1 (en) | 2022-03-31 | 2024-10-31 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
| TW202430176A (zh) | 2022-10-17 | 2024-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
| CN120712346A (zh) | 2023-01-31 | 2025-09-26 | 豪夫迈·罗氏有限公司 | 具有增加的酮还原酶活性的突变型酮还原酶以及涉及其的方法和用途 |
| EP4643858A1 (en) | 2024-04-29 | 2025-11-05 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for the treatment of uterine disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| NL7112938A (enEXAMPLES) * | 1970-09-30 | 1972-04-05 | ||
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| DK0958285T3 (da) * | 1997-01-08 | 2004-05-17 | Hoffmann La Roche | Tricykliske benzo[e]isoindoler og benzol[h]isoquinoliner |
| ES2152902B1 (es) * | 1999-07-27 | 2001-08-16 | Medichem Sa | Procedimiento de obtencion de venlafaxina |
| SI1315715T1 (sl) * | 2000-08-18 | 2008-12-31 | Millennium Pharm Inc | Kinazolinski derivati kot kinazni inhibitorji |
| EP1317447B1 (en) * | 2000-09-15 | 2006-05-17 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ES2365905T3 (es) * | 2001-03-30 | 2011-10-13 | King Pharmaceuticals, Inc. | Compuestos de tiofeno condensados y uso de los mismos en el tratamiento del dolor crónico. |
| CA2468266A1 (en) * | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Substituted bicyclic pyrimidinones as a mitotic kinesin ksp inhibitors |
| JP4469179B2 (ja) * | 2002-01-23 | 2010-05-26 | バイエル ファーマセチカル コーポレーション | Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体 |
| TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| CA2546754A1 (en) * | 2003-11-21 | 2005-06-09 | Array Biopharma Inc. | Akt protein kinase inhibitors |
| ATE464303T1 (de) * | 2004-04-28 | 2010-04-15 | Vertex Pharma | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen |
| WO2005113762A1 (en) | 2004-05-18 | 2005-12-01 | Pfizer Products Inc. | CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF |
| US20090131474A1 (en) * | 2005-03-03 | 2009-05-21 | Martino Forino | Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby |
| AU2007269052B2 (en) * | 2006-07-06 | 2014-10-23 | Array Biopharma Inc. | Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors |
| SI2054418T1 (sl) * | 2006-07-06 | 2012-02-29 | Array Biopharma Inc | Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji |
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
-
2007
- 2007-05-07 UA UAA200900764A patent/UA95641C2/ru unknown
- 2007-07-05 SG SG2012063863A patent/SG184706A1/en unknown
- 2007-07-05 MX MX2008016202A patent/MX2008016202A/es active IP Right Grant
- 2007-07-05 EP EP07799337A patent/EP2049501B1/en active Active
- 2007-07-05 KR KR1020097002395A patent/KR101178672B1/ko active Active
- 2007-07-05 KR KR1020157010625A patent/KR20150051240A/ko not_active Ceased
- 2007-07-05 AT AT07799337T patent/ATE524447T1/de active
- 2007-07-05 PL PL07799337T patent/PL2049501T3/pl unknown
- 2007-07-05 ES ES11166125.2T patent/ES2554252T3/es active Active
- 2007-07-05 ES ES11166123.7T patent/ES2554228T3/es active Active
- 2007-07-05 BR BR122013028005A patent/BR122013028005B8/pt active IP Right Grant
- 2007-07-05 KR KR1020127011042A patent/KR101495408B1/ko active Active
- 2007-07-05 HR HR20110908T patent/HRP20110908T1/hr unknown
- 2007-07-05 AU AU2007269060A patent/AU2007269060B2/en active Active
- 2007-07-05 SI SI200730780T patent/SI2049501T1/sl unknown
- 2007-07-05 DK DK07799337.6T patent/DK2049501T3/da active
- 2007-07-05 CN CN2012101841274A patent/CN102816124A/zh active Pending
- 2007-07-05 EP EP15178003.8A patent/EP2966065A3/en not_active Withdrawn
- 2007-07-05 PT PT07799337T patent/PT2049501E/pt unknown
- 2007-07-05 MX MX2019008117A patent/MX377920B/es unknown
- 2007-07-05 HU HUE11166125A patent/HUE026237T2/en unknown
- 2007-07-05 JP JP2009518636A patent/JP5266216B2/ja active Active
- 2007-07-05 BR BRPI0713923A patent/BRPI0713923B8/pt active IP Right Grant
- 2007-07-05 MX MX2015013326A patent/MX366319B/es unknown
- 2007-07-05 KR KR1020147017714A patent/KR20140093291A/ko not_active Ceased
- 2007-07-05 KR KR1020137031899A patent/KR101578877B1/ko active Active
- 2007-07-05 NZ NZ573732A patent/NZ573732A/en unknown
- 2007-07-05 BR BR122013028012A patent/BR122013028012B8/pt active IP Right Grant
- 2007-07-05 DK DK11166125.2T patent/DK2402325T3/en active
- 2007-07-05 WO PCT/US2007/072885 patent/WO2008006040A1/en not_active Ceased
- 2007-07-05 SG SG10201802127UA patent/SG10201802127UA/en unknown
- 2007-07-05 SG SG2012082871A patent/SG185980A1/en unknown
- 2007-07-05 SI SI200731699T patent/SI2402325T1/sl unknown
- 2007-07-05 NZ NZ610633A patent/NZ610633A/en unknown
- 2007-07-05 EP EP11166123.7A patent/EP2399909B1/en active Active
- 2007-07-05 CA CA2836316A patent/CA2836316A1/en not_active Abandoned
- 2007-07-05 CN CN2007800330851A patent/CN101578273B/zh active Active
- 2007-07-05 RS RS20110551A patent/RS52212B/sr unknown
- 2007-07-05 RU RU2009103900/04A patent/RU2478632C2/ru active
- 2007-07-05 EP EP11166125.2A patent/EP2402325B1/en active Active
- 2007-07-05 IN IN2886KON2014 patent/IN2014KN02886A/en unknown
- 2007-07-05 NZ NZ597647A patent/NZ597647A/xx unknown
- 2007-07-05 SG SG2013019468A patent/SG188905A1/en unknown
- 2007-07-05 ES ES07799337T patent/ES2372774T3/es active Active
- 2007-07-05 PL PL11166125T patent/PL2402325T3/pl unknown
- 2007-07-05 MY MYPI20090024A patent/MY147364A/en unknown
- 2007-07-05 CA CA2656622A patent/CA2656622C/en active Active
- 2007-07-06 AR ARP070103033A patent/AR061842A1/es not_active Application Discontinuation
- 2007-07-06 TW TW102117449A patent/TW201332994A/zh unknown
- 2007-07-06 TW TW096124780A patent/TWI402266B/zh active
- 2007-07-06 CL CL200701993A patent/CL2007001993A1/es unknown
-
2008
- 2008-12-17 MX MX2011010569A patent/MX337843B/es unknown
- 2008-12-18 IL IL196028A patent/IL196028A/en active IP Right Grant
-
2009
- 2009-01-05 ZA ZA200900070A patent/ZA200900070B/xx unknown
- 2009-02-03 MA MA31609A patent/MA31655B1/fr unknown
- 2009-02-04 CO CO09010508A patent/CO6150161A2/es unknown
- 2009-02-05 CR CR10600A patent/CR10600A/es unknown
- 2009-02-05 NO NO20090581A patent/NO342346B1/no unknown
-
2011
- 2011-12-08 CY CY20111101222T patent/CY1112117T1/el unknown
-
2012
- 2012-12-20 RU RU2012155606/04A patent/RU2012155606A/ru not_active Application Discontinuation
-
2013
- 2013-02-19 JP JP2013029956A patent/JP5836294B2/ja active Active
- 2013-06-26 JP JP2013133983A patent/JP2013177470A/ja active Pending
- 2013-12-05 AR ARP130104510A patent/AR093810A2/es unknown
-
2014
- 2014-09-16 JP JP2014188238A patent/JP2014231530A/ja not_active Withdrawn
-
2015
- 2015-09-20 IL IL241705A patent/IL241705A0/en unknown
-
2017
- 2017-08-25 AR ARP170102366A patent/AR109424A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR10600A (es) | Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa | |
| CR10601A (es) | Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt | |
| ECSP109937A (es) | Pirimidil ciclopentanos como inhibidores de la proteína quinasa akt. | |
| ATE522509T1 (de) | Pyrimidylcyclopentane als inhibitoren der akt- proteinkinase | |
| ECSP11010796A (es) | Compuestos de pirimidina, composiciones y métodos de uso | |
| DK2054418T3 (da) | Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer | |
| ECSP099445A (es) | Quinazolinas para la inhibición de pdk1 | |
| CR10573A (es) | Derivados del pirazol como inhibidores del citocromo p450 | |
| ECSP077268A (es) | Polimorfo ii de rapamicina y los usos de los mismos | |
| ATE493418T1 (de) | Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren | |
| ECSP088306A (es) | Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr | |
| DOP2010000013A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| CR11370A (es) | Inhibidores de quinasas simil polo | |
| DOP2009000242A (es) | Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer | |
| ECSP10010389A (es) | Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa | |
| CO6280510A2 (es) | Pirimidil ciclopentanos hidroxilados como inhibidores de akt proteina quinasa | |
| UA104410C2 (uk) | Піримідилциклопентани як інгібітори протеїнкіназ акт | |
| DOP2009000143A (es) | Quinazolinas para la inhibicion de pdk1 |